Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. - AlzForum Alzheimer Research Paper of the Week


	Current Papers
	ARF Recommends
	Milestone Papers
	Search All Papers
	Search Comments


	Research News
	Drug News
	Conference News


	AD Hypotheses
		AlzSWAN
		Current Hypotheses
		Hypothesis Factory
	Forums
		Live Discussions
		Virtual Conferences
		Interviews
	Enabling Technologies
		Workshops
		Research Tools
	Compendia
		AlzGene
		AlzRisk
		Antibodies
		Biomarkers
		Mutations
		Protocols
		Research Models
		Video Gallery
	Resources
		Bulletin Boards
		Conference Calendar
		Grants
		Jobs


	Overview
	Diagnosis/Genetics
	Research
	News
	Profiles
	Clinics


	Companies
	Tutorial
	Drugs in Clinical Trials


	About Alzheimer's
		FAQs
	Diagnosis
		Clinical Guidelines
		Tests
		Brain Banks
	Treatment
		Drugs and Therapies
	Caregiving
		Patient Care
		Support Directory
		AD Experiences


	Member Directory
	Researcher Profiles
	Institutes and Labs


	Mission
	ARF Team
	ARF Awards
	Advisory Board
	Sponsors
	Partnerships
	Fan Mail
	Support Us

Home: Papers of the Week

Annotation

	Patton RL, Kalback WM, Esh CL, Kokjohn TA, Van Vickle GD, Luehrs DC, Kuo YM, Lopez J, Brune D, Ferrer I, Masliah E, Newel AJ, Beach TG, Castaño EM, Roher AE. Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol. 2006 Sep;169(3):1048-63. PubMed Abstract, View on AlzSWAN

	Comments on Paper and Primary News

	Comment by: John Trojanowski, ARF Advisor
	Submitted 2 September 2006 \| Permalink	Posted 3 September 2006
	This is an important study of the consequences of Abeta immunization on Abeta peptides in patients treated with AN-1792. View all comments by John Trojanowski

	Comment by: Hilkka Soininen, ARF Advisor
	Submitted 3 September 2006 \| Permalink	Posted 3 September 2006
	I recommend this paper New data from immunization studies. View all comments by Hilkka Soininen

	Comment by: Charles Glabe, ARF Advisor
	Submitted 3 September 2006 \| Permalink	Posted 3 September 2006
	I recommend this paper Soluble Abeta levels are elevated in AN-1792 vaccinated patients. View all comments by Charles Glabe

	Comment by: Andre Delacourte, ARF Advisor
	Submitted 4 September 2006 \| Permalink	Posted 5 September 2006
	I recommend this paper

	Comment by: Lary Walker, ARF Advisor
	Submitted 5 September 2006 \| Permalink	Posted 5 September 2006
	I recommend this paper

Submit a Comment on this Paper

Cast your vote and/or make a comment on this paper.

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name
*Last Name
Country or Territory:
*Login Email Address
*Password	Minimum of 8 characters
*Confirm Password
Stay signed in?

I recommend this paper

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:

*Enter the verification code you see in the picture below:

This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:	Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.

REAGENTS/MATERIAL:

ELISA Ab 40 (Immuno-Biological Labs) and Ab 42 (Innogenetics) kits were used. Ab peptides were detected with anti-Ab40 and anti-Ab42 (Biosource, Camarillo, CA) as primary antibodies and goat anti-rabbit horseradish peroxidase conjugated as a secondary antibody (Pierce, Rockford, IL). Other antibodies were monoclonal 6E10 antibody against Ab residues 1 to 16, and monoclonal antibody 4G8 against Ab residues 17 to 24.




			Print this page Email this page Alzforum News Papers of the Week Text size Share & Bookmark Del.icio.us Digg Facebook Google Newsvine








			Antibodies Cell Lines Collaborators Papers Research Participants